Document Detail


Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation.
MedLine Citation:
PMID:  12107099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hyperhomocysteinemia (HHcy) is a newly recognized risk factor for myocardial infarction, however, the effect of HHcy on endothelium-dependent flow-induced dilation of coronary arteries is not known. Thus, changes in diameter of small intramural coronary arteries (diameter, approximately 145 microm) isolated from control rats and rats with methionine diet-induced HHcy were investigated by videomicroscopy. Increases in intraluminal flow (from 0 to 40 microl/min) elicited dilations of control vessels (maximum, 25 +/- 2 microm), responses that were absent in HHcy arteries. The nitric oxide (NO) synthase inhibitor L-NAME inhibited flow-induced dilation of control coronaries, whereas it had no effect on responses of HHcy arteries. Dilations of control and HHcy arteries to the NO donor sodium nitroprusside were not different. Responses to flow in HHcy coronary arteries were unaffected by administration of L-arginine or the prostaglandin H(2)/thromboxane A(2) receptor antagonist SQ 29,548. However, in the presence of superoxide dismutase (plus catalase) or the superoxide scavenger Tiron increases in flow elicited L-NAME-sensitive dilations of HHcy coronaries (maximum, 18 +/- 5 microm). Also, superoxide dismutase significantly reduced the enhanced superoxide production of HHcy coronaries (measured by the lucigenin chemiluminescence method). Single vessel Western blotting showed an increased tyrosine nitrosation (a stable biomarker of tissue peroxynitrite formation) in HHcy coronaries. Also, extensive prevalence of 3-nitrotyrosine immunoreactivity was observed in HHcy coronaries that was confined primarily to the subendothelial layers of smooth muscle. We propose that in HHcy an increased level of superoxide scavenges NO forming peroxynitrite, which increases protein nitrosation. The reduced bioavailability of NO impairs flow-induced dilations of coronary arteries, which may contribute to the development of coronary atherosclerosis and ischemic heart disease.
Authors:
Zoltan Ungvari; Anna Csiszar; Zsolt Bagi; Akos Koller
Related Documents :
8490289 - Effect of cold stress on coronary sinus blood flow in patients with scleroderma.
1132099 - Influence of hypertonic mannitol on ventricular performance and coronary blood flow in ...
9236429 - Intracoronary angiotensin ii potentiates coronary sympathetic vasoconstriction in humans.
9302359 - Mechanism of coronary microvascular responses to metabolic stimulation.
2963519 - Coronary vasodilatory action after a single dose of nicorandil.
3440269 - Effects of nifedipine on coronary reactive and exercise induced hyperaemia.
24975909 - Natriuretic peptides in heart failure with preserved ejection fraction.
22425819 - Cyclosporine treatment improves cardiac function and systemic hemodynamics during resus...
1591839 - Preconditioning does not attenuate myocardial stunning.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of pathology     Volume:  161     ISSN:  0002-9440     ISO Abbreviation:  Am. J. Pathol.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-10     Completed Date:  2002-08-06     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  0370502     Medline TA:  Am J Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  145-53     Citation Subset:  AIM; IM    
Affiliation:
Department of Pathophysiology, Semmelweis University, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blotting, Western
Coronary Circulation / drug effects,  physiology*
Coronary Vessels / metabolism
Enzyme Inhibitors / pharmacology
Hyperhomocysteinemia / pathology,  physiopathology*
Immunohistochemistry
Male
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide / physiology*
Peroxynitrous Acid / biosynthesis,  pharmacology
Rats
Rats, Wistar
Superoxides / metabolism
Tyrosine / analogs & derivatives*,  metabolism
Vasodilation*
Grant Support
ID/Acronym/Agency:
HL-46813/HL/NHLBI NIH HHS; P01-1HL-43023/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 10102-43-9/Nitric Oxide; 11062-77-4/Superoxides; 14691-52-2/Peroxynitrous Acid; 3604-79-3/3-nitrotyrosine; 50903-99-6/NG-Nitroarginine Methyl Ester; 55520-40-6/Tyrosine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endot...
Next Document:  STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers.